Alpha anomeric bicyclo DNA was invented and developed in the laboratory of Prof. Dr. Christian Leumann at the Department of Chemistry and Biochemistry of the University of Bern, Switzerland. Prof. Leumann is a leading expert in the design, synthesis and characterization of novel backbone modified nucleic acid analogues for antisense- and siRNA-therapy and we are collaborating with his laboratory for the further development of our platform.
About Us
What We Do | Alpha Anomeric
We are also collaborating closely with the laboratory of Prof. Dr. Annemieke Aartsma-Rus working at the department of Human Genetics at the Leiden University Medical Center (LUMC), in The Netherlands. Prof. Aartsma Rus is a leading expert in Duchenne muscular dystrophy and played an important role in the development of antisense mediated exon skipping therapy.
Meet Our Team
Board of Directors
Wolfgang Renner PhD, Président, holds a PhD degree in biotechnology from ETH Zürich since 1995. In the same year he co-founded Cytos Biotechnology AG and was CEO of Cytos until 2011, 9 years of which as a public company. From 2012 to 2017 he served as CEO of Synthena AG and in 2018 he co-founded Alpha Anomeric SAS which he leads as Président. He served as a member of the executive committee and of the foundation council of the Swiss National Science Foundation for 12 years. Wolfgang Renner received several awards, among them the Entrepreneur of the Year Award, the Swiss Economic Award, and the Award for Excellence in Biotech Business.
Raj joined Advent in 2005 bringing over 20 years of experience in biomedical research and as an entrepreneur and investor. After gaining an MA and DPhil from Oxford University, he pursued a successful academic career in molecular medicine before co-founding Oxford GlycoSciences (IPO on LSE and NASDAQ). Following its sale to UCB-Celltech, he became Chairman of Galapagos nv, a member of the Supervisory Board of the Novartis Venture Fund and a founding Director of Celldex Therapeutics. Since joining Advent, he has been involved with those portfolio Companies primarily engaged in the discovery of new medicines, including Avila, EUSA and Thiakis.
Investors
